candida
common
fungal
pathogen
human
fourth
lead
pathogen
nosocomi
bloodstream
infect
caus
wide
rang
infect
invas
superfici
variou
anatom
site
invas
candidiasi
associ
high
mortal
among
immunocompromis
popul
superfici
mucos
candidias
highli
preval
persist
especi
among
immunocompromis
patient
common
superfici
candidias
oral
candidiasi
candidaassoci
dentur
stomat
candidaassoci
dentur
stomat
could
affect
dentur
wearer
preval
candidiasiscaus
speci
candida
albican
versatil
morphogenesi
exist
three
form
ie
yeast
pseudohypha
hypha
two
lifestyl
plankton
biofilm
permit
c
albican
thrive
divers
environment
condit
particular
yeasttohypha
yh
transit
major
virul
attribut
facilit
tissu
invas
c
albican
addit
yh
transit
biofilm
format
host
tissu
abiot
devic
also
signific
basi
candida
infect
exampl
includ
candidaassoci
dentur
stomat
format
candida
biofilm
resist
antifung
agent
plankton
cell
directli
associ
treatment
failur
although
candida
infect
alway
pose
heavi
burden
public
health
situat
recent
worsen
first
worldwid
incid
candidiasi
increas
past
decad
may
attribut
increas
number
immunocompromis
patient
use
broadspectrum
antibiot
second
increas
incid
invas
candidiasi
caus
nonalbican
candida
nac
speci
candida
glabrata
candida
tropicali
candida
krusei
candida
parapsilosi
major
concern
infect
often
associ
higher
mortal
antifung
resist
caus
c
albican
lastli
emerg
antifung
resist
treatment
side
effect
restrict
treatment
option
alreadi
limit
arsen
current
antifung
agent
class
antifung
drug
polyen
azol
echinocandin
allylamin
dna
analogu
avail
candidiasi
treatment
drug
far
ideal
polyen
exampl
doserel
toxic
particularli
nephrotox
even
though
recent
introduct
lipid
formul
improv
riskbenefit
ratio
addit
rise
drug
resist
inevit
problem
pertin
fluconazol
drug
choic
treat
aid
patient
candida
infect
c
glabrata
c
krusei
intrins
resist
fluconazol
emerg
fluconazoleresist
c
albican
strain
also
rise
similarli
emerg
resist
also
report
recent
introduc
echinocandin
therefor
situat
like
amelior
discoveri
introduct
safe
new
antifung
agent
small
molecul
invalu
sourc
novel
antifung
agent
previou
screen
smallmolecul
librari
result
identif
novel
compound
effect
sever
acut
respiratori
syndromeassoci
coronaviru
sought
small
molecul
anticandida
properti
overal
strategi
depict
figur
first
screen
collect
small
molecul
inhibitor
yh
transit
c
albican
identifi
hit
assess
antifung
antibiofilm
activ
led
us
discov
novel
antifung
small
molecul
design
examin
vitro
antifung
activ
well
vivo
efficaci
mous
infect
model
oral
system
candidias
last
potenti
mechan
action
also
investig
highthroughput
screen
perform
chemic
genet
unit
depart
microbiolog
research
center
infect
immunolog
li
ka
shing
faculti
medicin
univers
hong
kong
librari
small
molecul
chembridg
san
diego
ca
usa
identifi
inhibitor
yh
transit
c
albican
previous
describ
c
albican
seed
cell
per
well
complet
yeast
pepton
dextros
ypd
yeast
extract
pepton
glucosedextros
supplement
heatinactiv
foetal
bovin
serum
invitrogen
carlsbad
ca
usa
total
volum
microtitr
plate
small
molecul
dissolv
dimethyl
sulfoxid
dmso
ad
well
final
concentr
wherea
control
contain
amount
dmso
without
small
molecul
assay
plate
incub
h
morpholog
candida
score
use
leica
dmil
invert
microscop
equip
digit
imag
system
leica
microsystem
heidelberg
germani
small
molecul
lower
score
control
yeasttohypha
transit
inhibitor
select
primari
hit
dosedepend
yh
inhibit
primari
hit
examin
use
refer
strain
c
albican
ten
clinic
isol
c
albican
strain
oral
origin
archiv
collect
oral
bioscienc
faculti
dentistri
univers
hong
kong
robust
hyphainduc
condit
lee
medium
incub
sampl
contain
candida
suspens
cfusml
small
molecul
differ
final
concentr
incub
h
cell
morpholog
observ
light
microscopi
olympu
tokyo
japan
degre
yh
inhibit
quantifi
calcul
percentag
hyphal
cell
one
hundr
cell
singl
sampl
count
perform
quadrupl
sampl
minimum
inhibitori
concentr
mic
yh
transit
micyh
determin
minimum
concentr
hypha
observ
assay
perform
three
differ
occas
duplic
antifung
activ
small
molecul
assess
disk
diffus
broth
dilut
assay
see
use
four
group
candida
isol
first
group
consist
atcc
strain
c
albican
atcc
qualiti
control
strain
c
glabrata
atcc
c
krusei
atcc
c
parapsilosi
atcc
c
tropicali
atcc
three
group
clinic
isol
bloodstream
isol
queen
mari
hospit
queen
elizabeth
hospit
hong
kong
oral
isol
nasopharyng
carcinoma
patient
queen
mari
hospit
hong
kong
dentur
stomat
clinic
isol
archiv
collect
oral
bioscienc
faculti
dentistri
univers
hong
kong
isol
subcultur
sabouraud
dextros
agar
sda
incub
aerob
overnight
assay
assay
perform
three
differ
occas
duplic
per
isol
standard
disk
diffus
assay
clinic
laboratori
standard
institut
clsi
use
brief
cfusml
yeast
suspens
prepar
isol
phosphatebuff
salin
pb
distribut
evenli
spiral
plater
muellerhinton
mh
agar
supplement
glucos
methylen
blue
antifung
tablet
amphotericin
b
caspofungin
ketoconazol
fluconazol
neosensitab
rosco
diagnostica
taastrup
denmark
use
posit
control
paper
coupon
place
agar
either
small
molecul
pb
neg
control
ad
onto
coupon
mh
agar
plate
incub
aerob
h
diamet
result
inhibit
zone
measur
standard
protocol
broth
microdilut
assay
clsi
follow
modif
yeast
suspens
approxim
coloni
form
unit
per
millilitr
cfusml
prepar
rpmi
medium
life
technolog
new
york
usa
ad
microtitr
plate
iwaki
tokyo
japan
serial
dilut
small
molecul
prepar
medium
ad
well
amphotericin
b
use
posit
control
plate
incub
h
candida
growth
well
bottom
visual
observ
determin
minimum
inhibitori
concentr
mic
activ
cryptococcu
neoforman
aspergillu
fumigatu
penicillium
marneffei
similarli
assess
h
incub
candida
biofilm
form
accord
previous
describ
method
brief
yeast
cell
subcultur
sda
incub
aerob
h
transfer
yeast
nitrogen
base
ynb
liquid
medium
supplement
mm
glucos
incub
aerob
rpm
overnight
harvest
cell
wash
twice
ml
pb
resuspend
densiti
cfusml
ynb
medium
supplement
mm
glucos
well
microtitr
plate
iwaki
inocul
yeast
suspens
cell
allow
adher
well
bottom
incub
rpm
h
adhes
phase
biofilm
wash
pb
remov
nonadher
cell
fresh
medium
ad
well
biofilm
incub
rpm
h
screen
assay
small
molecul
ad
biofilm
adhes
phase
effect
matur
biofilm
investig
ad
biofilm
h
h
cell
viabil
treat
biofilm
measur
xtt
reduct
assay
medium
well
discard
xtt
solut
ad
xtt
solut
consist
xtt
stock
solut
mgml
pb
menadion
mm
aceton
pb
microtitr
plate
incub
dark
h
xtt
solut
well
transfer
new
microtitr
plate
absorb
measur
nm
minimum
inhibitori
concentr
biofilm
micbiofilm
determin
concentr
caus
reduct
cell
viabil
assay
perform
three
differ
occas
duplic
coldcur
polymethylmethacryl
pmma
disc
prepar
accord
manufactur
instruct
vertex
rs
vertexdent
bv
zeist
netherland
describ
previous
modif
brief
transpar
selfpolymeris
acryl
powder
mix
monom
liquid
ratio
wv
mixtur
immedi
spread
onto
press
tightli
two
aluminium
foilcov
glass
slide
secur
two
binder
clip
ensur
similar
thick
surfac
result
acryl
strip
cure
min
bar
strip
care
retriev
cut
squar
strip
immers
distil
water
day
remov
excess
monom
disinfect
alcohol
min
wash
thrice
steril
distil
water
simul
condit
present
mouth
promot
candida
adhes
strip
treat
saliva
min
saliva
collect
five
healthi
volunt
centrifug
g
min
result
supernat
store
use
c
albican
isol
identifi
stronger
biofilm
former
previou
studi
subcultur
sda
one
day
assay
yeast
inoculum
standardis
cfusml
ynb
supplement
mm
glucos
acryl
strip
place
plate
iwaki
ml
yeast
inoculum
ad
well
complet
cover
acryl
strip
ad
micbiofilm
adhes
phase
adhes
phase
assess
h
inocul
plate
place
shake
incub
cell
viabil
biofilm
acryl
strip
quantifi
xtt
reduct
assay
also
observ
confoc
laser
scan
microscopi
olympu
fluoview
stain
use
livedead
baclight
viabil
kit
invitrogen
engin
c
albican
strain
express
gfp
control
either
promot
gift
dr
b
p
krom
strain
use
test
effect
express
strain
cultiv
overnight
lee
medium
contain
mic
gfp
express
observ
use
confoc
laser
scan
microscopi
olympu
fluoview
disk
diffus
assay
clsi
also
use
assess
potenti
activ
six
bacteri
speci
escherichia
coli
lactobacillu
acidophilu
streptococcu
mutan
streptococcu
miti
streptococcu
sanguini
aggregatibact
actinomycetemcomitan
bacteria
subcultur
one
day
assay
bacteri
cell
suspens
prepar
sampl
densiti
cfusml
distribut
evenli
sheep
blood
agar
plate
spiral
plater
paper
coupon
inocul
drug
control
amphotericin
b
caspofungin
place
agar
chlorhexidin
glucon
use
posit
antibacteri
control
pb
neg
harmless
control
plate
incub
anaerob
except
e
coli
plate
h
diamet
inhibit
zone
measur
efficaci
antifungalresist
candida
strain
evalu
antifung
suscept
test
broth
microdilut
disk
diffus
assay
describ
strain
clinic
blood
isol
belong
variou
candida
spp
obtain
helsinki
univers
central
hospit
helsinki
finland
confirm
resist
one
antifung
agent
standard
clsi
antifung
suscept
test
previou
studi
primari
human
oral
keratinocyt
hok
sciencel
research
laboratori
carlsbad
ca
usa
passag
three
seed
plate
iwaki
oral
keratinocyt
medium
sciencel
research
laboratori
serumfre
medium
contain
oral
keratinocyt
growth
supplement
penicillin
streptomycin
well
initi
contain
approxim
hok
incub
presenc
medium
chang
everi
day
cell
reach
confluenc
dilut
seri
suppli
well
well
contain
medium
total
plate
incub
h
viabil
hok
determin
mtt
assay
see
flask
also
use
assess
cell
viabil
presenc
besid
hok
human
gingiv
fibroblast
hgf
monocyt
cell
line
sciencel
research
laboratori
also
use
cell
line
seed
flask
confluenc
reach
ml
growth
medium
final
concentr
ad
flask
comparison
amphotericin
b
use
concentr
hincub
mtt
assay
perform
measur
cell
viabil
mtt
bromid
yellow
tetrazolium
dye
convert
purpl
compound
mitochondri
enzym
mtt
solut
mgml
prepar
growth
medium
ad
well
flask
incub
h
dark
mtt
solut
discard
convert
dye
solubilis
equal
amount
dmso
absorb
convert
dye
measur
nm
background
subtract
nm
concentr
cell
viabil
drop
record
cytotox
concentr
hok
cultur
perform
mention
hok
passag
three
seed
plate
ibidi
martinsri
germani
compat
observ
confoc
laser
scan
microscop
cell
incub
presenc
confluenc
reach
medium
chang
everi
day
well
contain
approxim
hok
confluenc
cell
wash
pb
fresh
medium
without
antibiot
antibiot
could
inhibit
candida
growth
ad
suspens
c
albican
cfusml
obtain
subcultur
sda
plate
incub
one
day
inocul
prepar
growth
medium
without
antibiot
cell
suspens
ad
well
ad
variou
final
concentr
wherea
posit
control
contain
growth
medium
plate
incub
h
presenc
viabil
hok
yeast
cell
assess
confoc
laser
scan
microscopi
use
fluoresc
probe
livedead
baclight
viabil
kit
livedead
viabilitycytotox
kit
mammalian
cell
invitrogen
anim
studi
strictli
follow
recommend
guid
care
use
laboratori
anim
publish
nation
institut
health
protocol
approv
committe
use
live
anim
teach
research
culatr
univers
hong
kong
permit
number
mice
use
male
mice
obtain
laboratori
anim
unit
univers
hong
kong
mous
model
system
candidiasi
establish
accord
previous
describ
method
modif
mice
inject
via
tail
vein
cell
suspens
c
albican
cfusml
h
start
antifung
treatment
drug
given
mice
twice
day
day
via
intraperiton
inject
test
group
n
treat
mgkg
pb
control
group
n
treat
pb
mice
weigh
everi
day
mice
sacrif
day
kidney
harvest
candida
cell
system
candidiasi
murin
model
found
kidney
kidney
divid
equal
portion
fungal
burden
determin
histopatholog
evalu
fungal
burden
determin
kidney
weigh
homogenis
pb
homogen
serial
dilut
plate
sda
plate
incub
fungal
burden
express
ratio
coloni
form
unit
cfu
organ
weight
histopatholog
analysi
organ
fix
paraformaldehyd
embed
paraffin
wax
stain
period
acidschiff
pa
murin
model
oral
candidiasi
establish
accord
previous
describ
method
one
day
infect
mice
immunosuppress
subcutan
inject
two
dose
prednisolon
mgkg
bodi
weight
antibiot
tetracyclin
hydrochlorid
mgml
administ
drink
water
immedi
infect
mice
anesthetis
chlorpromazin
chlorid
mgml
via
intramuscular
inject
femur
oral
caviti
anesthetis
mice
swab
sterilis
cotton
swab
dip
cell
suspens
c
albican
cfusml
cultur
grown
overnight
sda
subsequ
n
nystatin
n
pb
control
n
administ
mice
pipet
mouth
done
five
time
h
inocul
mice
sacrif
h
infect
immedi
observ
macroscop
tongu
lesion
tongu
lesion
degre
evalu
use
score
system
denot
healthi
tongu
surfac
sever
stage
entir
oral
caviti
mice
swab
sterilis
cotton
swab
submerg
pb
vortex
vigor
result
suspens
spiral
plate
sda
number
cfu
count
incub
h
addit
invas
tongu
tissu
candida
evalu
histolog
pa
stain
describ
propidium
iodid
membraneimperm
fluoresc
dye
bind
nucleic
acid
wide
use
differenti
cell
damag
plasma
membran
healthi
one
evalu
effect
fungal
plasma
membran
c
albican
cell
approxim
cfusml
obtain
logarithm
phase
cultur
suspend
rpmi
medium
describ
cell
expos
submic
h
gentl
shake
subsequ
cell
harvest
incub
propidium
iodid
use
livedead
baclight
viabil
kit
invitrogen
min
observ
confoc
microscopi
olympu
fluoview
oneway
analysi
varianc
anova
employ
evalu
mean
differ
control
test
group
statist
signific
data
analyz
use
spss
softwar
packag
spss
version
spss
inc
chicago
il
usa
data
consid
signific
pvalu
less
obtain
small
molecul
inhibitor
candida
spp
first
screen
small
molecul
inhibitor
yh
transit
c
albican
activ
compound
identifi
eight
compound
display
strong
dosedepend
yh
inhibit
hyphainduc
condit
refer
strain
c
albican
ten
clinic
isol
c
albican
figur
eight
compound
four
form
inhibit
zone
disk
diffus
assay
use
standard
refer
strain
c
albican
atcc
indic
fungicid
activ
result
shown
figur
addit
potent
antibiofilm
activ
four
compound
figur
therefor
molecular
weight
gmol
chembridg
id
previous
identifi
antifung
agent
chosen
studi
figur
examin
yh
inhibit
phenotyp
panel
candida
isol
includ
refer
strain
c
albican
ten
c
albican
clinic
isol
oral
origin
observ
robust
hyphainduc
condit
presenc
control
ad
extens
hypha
could
observ
incub
contrast
yeast
cell
hypha
could
observ
sampl
lace
concentr
higher
figur
micyh
equival
cfusml
c
albican
figur
similar
averag
micyh
ten
clinic
isol
tabl
furthermor
micyh
directli
proport
cell
densiti
tabl
addit
use
c
albican
strain
test
whether
affect
express
gfp
express
candid
hypha
untreat
condit
observ
confoc
fluoresc
microscopi
figur
contrast
trace
fluoresc
could
detect
cell
micyh
suggest
influenc
express
ideal
antifung
agent
activ
fungal
speci
bacteria
antifung
activ
exhibit
disk
diffus
assay
broth
microdilut
assay
form
inhibit
zone
c
albican
c
albican
atcc
clinic
isol
test
averag
diamet
inhibit
zone
isol
mm
rang
mm
growth
inhibit
zone
c
albican
c
albican
atcc
shown
figur
broth
microdilut
assay
mic
c
albican
atcc
found
similar
convent
antifung
amphotericin
b
suggest
compar
potenc
tabl
mic
wide
rang
candida
spp
includ
clinic
isol
fungal
speci
except
fumigatu
rang
tabl
lower
suscept
note
fungu
fumigatu
mic
also
observ
amphotericin
b
mic
inhibit
growth
six
bacteri
speci
evalu
disk
diffus
assay
impli
fungal
specif
novel
molecul
figur
assess
activ
candida
biofilm
format
first
use
microtitrepl
biofilm
model
ad
biofilm
c
albican
c
glabrata
c
krusei
demonstr
lower
micbiofilm
amphotericin
b
caspofungin
biofilm
tabl
vitro
model
dentur
stomat
effect
prevent
candid
adhes
biofilm
develop
dentur
acryl
surfac
figur
model
biofilm
viabil
reduc
ad
h
adhes
phase
respect
figur
summar
two
assay
effect
matur
candida
biofilm
inhibit
biofilm
format
dentur
acryl
surfac
emerg
antifungalresist
candida
strain
led
urgent
need
new
antifung
agent
drugresist
isol
test
suscept
instanc
clear
inhibit
zone
observ
multidrugresist
c
guilliermondii
strain
figur
mic
drugresist
candida
isol
broth
microdilut
assay
rang
tabl
margin
higher
mic
c
albican
atcc
cytotox
assay
perform
plate
reveal
hok
assay
conduct
flask
reduc
viabil
hok
compar
untreat
control
lower
reduct
observ
amphotericin
b
treatment
amphotericin
b
caus
respect
reduct
monocyt
viabil
compar
control
neither
amphotericin
b
affect
viabil
hgf
figur
test
whether
abl
prevent
c
albican
invas
human
cell
cocultur
hok
c
albican
expos
variou
concentr
cocultur
control
present
mani
hypha
observ
hyphal
invad
caus
death
hok
figur
candida
hypha
could
still
observ
howev
proport
live
hok
increas
hok
aliv
candida
observ
therefor
concentr
safe
hok
suffici
prevent
candida
invad
human
cell
mous
model
system
candidiasi
use
assess
vivo
activ
infect
establish
mice
inject
cfusml
c
albican
via
tail
vein
test
group
treat
mgkg
control
group
treat
pb
day
experiment
end
point
infect
c
albican
untreat
mice
system
candidiasi
die
wherea
mice
aliv
figur
fungal
burden
kidney
significantli
lower
mice
untreat
one
figur
moreov
white
candida
lesion
visibl
cover
surfac
kidney
untreat
mice
kidney
mice
appear
healthi
figur
cluster
candida
hypha
easili
identifi
passtain
kidney
untreat
mice
wherea
candida
cell
observ
kidney
parenchyma
mice
figur
result
indic
effect
prevent
system
spread
invas
candida
mous
model
assess
effect
nystatin
treatment
mous
model
oral
candidiasi
establish
inocul
c
albican
cfusml
oral
caviti
mice
treatment
given
mice
five
time
interv
immedi
sacrific
h
inocul
score
assign
tongu
lesion
healthi
tongu
surfac
sever
stage
thick
oral
thrush
observ
untreat
mice
score
figur
tongu
lesion
nystatintr
mice
less
sever
untreat
control
although
consider
oral
thrush
note
back
tongu
score
compar
two
group
mice
display
least
sever
tongu
lesion
score
moreov
candida
cell
count
tongu
swab
mice
cfusml
consist
lower
control
mice
cfusml
nystatintr
anim
cfusml
numer
candid
hypha
note
passtain
tongu
section
untreat
mice
wherea
less
profus
candid
growth
observ
sampl
mice
treat
nystatin
figur
shed
light
mechan
action
perform
propidiumiodid
uptak
assay
candida
expos
submic
display
abund
propidium
iodid
uptak
indic
cell
membran
damag
figur
therefor
molecular
target
might
compon
cell
membran
hand
small
molecul
report
possess
activ
c
albican
howev
therapeut
potenti
small
molecul
unclear
evalu
mainli
abil
inhibit
c
albican
virul
properti
yh
transit
biofilm
format
vitro
hypothesis
arrest
candida
unicellular
yeast
form
would
result
reduc
virul
hypothesi
support
find
nonfilament
c
albican
mutant
virul
mous
infect
model
howev
relev
c
albican
nac
speci
form
true
hypha
also
virul
moreov
strategi
inhibit
virul
factor
could
facilit
emerg
resist
strain
inhibit
growth
virul
strain
kill
complet
elimin
pathogen
clearli
safer
option
therefor
fungicid
drug
prefer
reason
set
identifi
new
antifung
compound
fungicid
antivirul
properti
end
first
screen
yh
inhibitor
librari
small
molecul
note
yh
inhibitor
screen
assay
select
molecul
block
chang
yeast
form
c
albican
hyphal
form
assess
morpholog
therefor
assay
discrimin
molecul
inhibit
growth
c
albican
would
also
prevent
yh
transit
true
inhibitor
yh
transit
moreov
convent
antifung
agent
fluconazol
amphotericin
b
whose
mechan
directli
relat
yh
inhibit
also
inhibit
format
hypha
nevertheless
ambigu
screen
assay
favour
increas
hit
rate
initi
screen
sever
vitro
analys
antifung
properti
small
molecul
identifi
initi
screen
found
one
potent
yh
inhibitor
effect
low
concentr
among
yh
inhibitor
identifi
studi
midkiff
et
al
lowest
micyh
cell
much
higher
micyh
cfusml
number
candida
decreas
treatment
vitro
suggest
compound
fungicid
fungicid
drug
inhibit
yh
transit
submic
wherea
fungistat
drug
inhibit
yh
transit
much
higher
concentr
mic
suggest
fungicid
drug
inhibit
hyphal
develop
bud
process
wherea
fungistat
drug
inhibit
bud
process
vitro
antifung
activ
compar
commonli
use
antifung
drug
amphotericin
b
polyen
disk
diffus
assay
form
clear
inhibit
zone
resembl
produc
polyen
echinocandin
unlik
partial
inhibit
zone
form
azol
trail
endpoint
observ
mic
broth
microdilut
assay
wide
rang
c
albican
strain
similar
mic
amphotericin
b
consid
gold
standard
antifung
agent
moreov
activ
c
albican
biofilm
grown
microtitr
plate
similar
potent
amphotericin
b
caspofungin
tabl
micbiofilm
increas
biofilm
matur
common
phenomenon
among
antifung
agent
attach
mucos
tissu
biofilm
format
basi
mucos
candidias
oral
candidiasi
candidaassoci
dentur
stomat
effect
reduc
candid
attach
dentur
acryl
surfac
inhibit
biofilm
develop
vitro
model
dentur
stomat
promis
data
indic
might
potenti
dentur
disinfect
activ
ingredi
oral
drug
deliveri
system
also
analys
vivo
effect
treatment
mous
model
oral
system
candidiasi
show
oral
rins
contain
significantli
reduc
tongu
lesion
oral
candidiasi
mous
model
moreov
efficaci
better
nystatin
commonli
use
antifung
oral
candidiasi
particular
oral
thrush
observ
back
tongu
nystatintr
mice
indic
oropharyng
candidiasi
anim
howev
littl
known
pharmacokinet
pharmacodynam
nystatin
murin
model
oral
candidiasi
therefor
concentr
use
experi
might
high
enough
produc
optim
outcom
addit
durat
oral
rins
control
mous
model
evalu
toxic
human
cell
line
vitro
contrast
bacteria
cell
fungi
human
eukaryot
therefor
similar
similar
major
hurdl
antifung
develop
requir
drug
target
fungusspecif
avoid
undesir
toxic
found
hok
plate
assay
although
valu
lower
minimum
report
antifung
compound
identifi
lafleur
et
al
test
human
fibroblast
plate
still
higher
mic
indic
rang
concentr
could
use
antifung
agent
without
caus
signific
toxic
human
cell
inde
detriment
effect
observ
mice
inject
dose
high
mgkg
twice
daili
addit
seem
antibacteri
properti
indic
target
present
fungi
bacteria
demonstr
intraperiton
administr
effect
treatment
system
candidiasi
mous
model
dose
mgkg
higher
twice
daili
begin
h
postinfect
significantli
reduc
fungal
burden
nonneutropen
mice
vivo
efficaci
similar
convent
antifung
agent
compar
nonneutropen
mous
model
system
c
albican
candidiasi
exampl
intraperiton
effect
dose
fluconazol
mgkg
administ
mice
singl
dose
h
infect
anim
sacrif
h
later
intraperiton
amphotericin
b
mgkg
dose
daili
decreas
fungal
burden
mous
kidney
day
day
infect
treatment
begin
h
infect
addit
intraven
micafungin
treatment
mgkg
higher
daili
dose
start
h
infect
day
prolong
surviv
infect
mice
howev
difficult
compar
effect
dose
differ
studi
standard
protocol
differ
candida
strain
inoculum
size
mous
strain
mous
immun
statu
start
interv
antifung
therapi
could
interfer
outcom
addit
differ
vivo
drug
efficaci
among
normal
neutropen
murin
model
may
due
possibl
interact
drug
host
defenc
mechan
detail
pharmacodynamicspharmacokinet
studi
would
need
perform
futur
determin
timeconcentr
relationship
drug
infect
site
thu
gener
dose
regimen
produc
best
treatment
outcom
vivo
effect
antifungalresist
clinic
isol
indic
mechan
action
distinct
convent
antifung
preliminari
result
describ
indic
could
target
compon
fungal
cell
membran
nevertheless
extens
assay
need
elucid
mechan
action
new
drug
conclus
present
studi
characteris
novel
antifung
small
molecul
use
comprehens
set
vitro
vivo
assay
find
support
promis
compound
develop
novel
antifung
agent
treat
local
system
candidiasi
could
bring
enorm
benefit
patient
suffer
recalcitr
fungal
pathogen
